Express News | Kenneth Griffin Reports 5.3% Passive Stake In Terns Pharmaceuticals As Of July 10
Express News | Kenneth Griffin Reports 5.3% Passive Stake in Terns Pharmaceuticals as of July 10 - SEC Filing
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Form 144 | Terns Pharmaceuticals(TERN.US) Director Proposes to Sell 9.09 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 15, $Terns Pharmaceuticals(TERN.US)$ Director OrbiMed Private Investments VII, LP intends to sell 976.8K shares of its common stock on Jul 15, with a total market value
Mizuho Securities Maintains Terns Pharmaceuticals(TERN.US) With Buy Rating
Mizuho Securities Keeps Their Buy Rating on Terns Pharmaceuticals (TERN)
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
GLP-1 Agonists Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, Inc., Eccogene, AstraZeneca
Express News | Terns Pharmaceuticals Shares Are Trading Higher After the Company Announced That It Will Present Preclinical Data Supporting TERN-501 in Combination With a GLP-1 Receptor Agonist for Obesity at the American Diabetes Association 84th Scientific Sessions
Reported Earlier, Terns Pharmaceuticals Unveils Preclinical Data on Obesity Treatment at ADA 2024
Express News | Terns Pharmaceuticals Highlights New Preclinical Data Supporting Tern-501 in Combination With a Glp-1R Agonist for Obesity at the Ada’s 84TH Annual Scientific Sessions and Upcoming Conference Participation
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's Is How to Trade
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Buy Rating Upheld for Terns Pharmaceuticals Amid Strong Prospects for TERN-701 and Financial Stability
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
Optimistic Buy Rating for Terns Pharmaceuticals Amid Promising Clinical Progress and Solid Financial Footing
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and OptimizeRx (OPRX)